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ABSTRACT
The potential use of antisense and siRNA oligonu-
cleotides as therapeutic agents has elicited a
great deal of interest. However, a major issue for
oligonucleotide-based therapeutics involves effec-
tive intracellular delivery of the active molecules. In
this Survey and Summary, we review recent reports
on delivery strategies, including conjugates of
oligonucleotides with various ligands, as well as
use of nanocarrier approaches. These are discussed
in the context of intracellular trafficking pathways
and issues regarding in vivo biodistribution of mole-
cules and nanoparticles. Molecular-sized chemical
conjugates and supramolecular nanocarriers each
display advantages and disadvantages in terms of
effective and nontoxic delivery. Thus, choice of an
optimal delivery modality will likely depend on the
therapeutic context.
OVERVIEW
Antisense and siRNA oligonucleotides hold great promise
as therapeutic agents. Several ﬁrst generation (phosphor-
othioate) antisense oligonucleotides are in late phase
clinical testing (1–4), while newer oligonucleotide chemis-
tries are providing antisense molecules with higher binding
aﬃnities, greater stability and lower toxicity as clinical
candidates (5–7). The rapid development of mammalian
RNA interference (RNAi) opens the path to a powerful
new strategy for therapeutic regulation of gene expression
(8–12). Promising results have been attained with small
interfering RNAs (siRNAs) in animal models (13–15) and
several clinical trials are underway (13). However, despite
abundant promise, a number of problems and hurdles
remain for oligonucleotide-based therapeutics. Perhaps
the most important issue concerns the eﬀective delivery of
antisense or siRNA oligonucleotides to their respective
sites of action in the nucleus or cytoplasm. In studies of
cells in culture, delivery agents such as cationic lipids or
polymers are required in order to attain signiﬁcant
antisense or siRNA eﬀects. However, the large size
and/or considerable toxicity (16,17) of cationic lipid
particles and cationic polymers may render them problem-
atic candidates for in vivo utilization. In contrast, many
animal studies and virtually all of the clinical studies thus
far have used ‘free’ antisense or siRNA compounds
(without a delivery agent), thereby demonstrating that
oligonucleotides can function in that form. However,
many investigators believe that appropriate delivery plat-
forms could be very helpful for oligonucleotide-based
therapeutics (18–20). In this Survey and Summary, we
review and analyze chemically based approaches to
oligonucleotide delivery, including use of nanocarriers
and molecular conjugates. These approaches will be con-
sidered both in terms of intracellular delivery to cultured
cells and in terms of in vivo biodistribution. Obviously,
another important therapeutic strategy will be to use viral
vectors for siRNA expression (10,12,21–24), but we will
not further consider the viral approach in this review.
BACKGROUND
Antisense andsiRNA mechanisms
Here, we brieﬂy summarize aspects of the chemistry and
biology of antisense and siRNA oligonucleotides that are
salient to their potential as therapeutic agents.
Antisense. RNaseH-mediated degradation of complemen-
tary mRNA is the major mode of action of antisense
oligonucleotides. However, oligonucleotides that do not
support RNaseH can aﬀect gene expression by translation
arrestorbyalteringsplicing(25).Targetsiteselectioninthe
mRNA is an important issue and remains rather empirical.
Simple phosphodiester oligonucleotides are unstable in the
biological milieu; thus, a number of chemically modiﬁed
oligonucleotides have been developed to enhance stability
and to confer other desirable properties (3,5,6).
Substitution of sulfur for oxygen forms phosphorothioate
oligonucleotides, the most common modiﬁcation.
However, several other highly improved oligonucleotide
chemistries have emerged including 20-OH modiﬁcations,
locked nucleic acids (LNAs), peptide nucleic acids (PNAs),
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All of these entities have high aﬃnities for RNA and are
more stable than phosphorothioates; however, they do not
support RNaseH activity (5–7). Thus oligomers based
entirely on these chemistries cannot be used as ‘classic’
antisense agents (although they may be very eﬀective for
modiﬁcation of splicing or translation arrest). Introduction
ofseveralcentralphosphodiesterresiduesintotheseagents,
thereby creating ‘gapmers’, results in antisense oligonu-
cleotidesthatactivateRNaseHbutthatalsoretainmanyof
the desirable properties of the parent compounds (7).
siRNA. Suppression by double-stranded RNA (dsRNA)
is an important endogenous mechanism of gene regula-
tion, acting through pathways involving mRNA degrada-
tion and/or sequestration, translation arrest and eﬀects on
chromatin and transcription (26). The mRNA cleaving
action of interfering dsRNA in mammals involves
two enzymatic steps. First, the ‘Dicer’ enzyme and its
co-factors cleaves dsRNA to 21- to 23-mer segments
(siRNA) and assists its’ loading on to the Argonaute 2
(Ago 2)-containing ‘RISC’ complex. RISC removes the
sense strand, pairs the antisense (guide) strand with a
complementary region in the cognate mRNA and initiates
cleavage (‘slicing’) at a site between bases 10 and 11,
relative to the 50 end of the antisense strand (21,27–29).
The resulting 50 and 30 mRNA fragments are subsequently
fully degraded by several cellular nucleases (26,30).
In addition to ‘slicer’ activity, which requires essentially
complete complementarity between the siRNA guide
strand and its target, short dsRNAs can also display
miRNA activity against partially complementary
sequences in the 30-regulatory regions of mRNAs. While
bound to Ago protein complexes, the ‘seed region’ of the
antisense strand (positions 2–7, 8 from the 50 end) pairs
precisely with the target, while some mismatches are
tolerated in other regions. This process can lead to arrest
of translation, sequestration of the target mRNA in
cytosolic P-bodies (which are key sites of RNA proces-
sing), and possibly to de-capping and degradation (26,31).
Thus, miRNA-mediated actions can potentially lead to
oﬀ-target eﬀects of siRNAs. In addition to the ‘slicer’ and
miRNA pathways, dsRNA can also regulate transcription
at the chromatin level via processes that are not yet fully
elucidated (32). There is also an interesting conjunction
between siRNA eﬀects and antisense mechanisms. Thus,
antisense oligonucleotides can be designed to interrupt the
function of endogenous miRNAs. Since miRNAs often
reduce gene expression, these antisense agents (sometimes
termed ‘antagomirs’) can cause upregulation of expression
of some of the genes that are regulated by a particular
miRNA (11,33–35).
In mammals, long dsRNAs elicit highly toxic responses
related to the eﬀects of viral infection and interferon
production (8,28). To avoid this, Tuschl and colleagues
initiated the use of short interfering RNAs (siRNAs),
comprised of 19-mer duplexes with 2 base 30 overhangs on
each strand, that associate with Ago2 and selectively
degrade targeted mRNAs (36). Short, chemically synthe-
sized, siRNAs do not require the Dicer step, although
Dicer-enhanced RISCloading maycontribute toeﬃciency.
To enhance siRNA eﬀectiveness a variety of chemical
modiﬁcations have been pursued including alterations in
the backbone chemistry, 20-sugar modiﬁcations, altered
ring structure, nucleobase modiﬁcations and others
(37–40), and the importance of these modiﬁcations to
potential clinical applications has been emphasized (41).
In terms of overall design, understanding of the biochem-
ical mechanism of RNA interference has provided
important guidelines; ﬁrst, the siRNA must maintain an
A-form (RNA-like) duplex, second the 5-position on the
antisense strand must be able to be phosphorylated, third
to be eﬀective siRNAs should have low thermodynamic
stability in the 50 antisense region (26,40,42). These general
design principles can then be further reﬁned through the
use of appropriate chemical modiﬁcations (39).
It is important to note, however, that siRNA biology is
complex, and that it is essential to validate the mechanisms
underlying observed biological eﬀects before attributing
them to RNA interference. A dramatic example of this
concerns a recent study of siRNAs designed to ameliorate
macular degeneration by targeting VEGF or its receptor
and thus suppressing angiogenesis in the eye. A compre-
hensive analysis of the situation revealed that the observed
reduction of angiogenesis was not due to sequence-speciﬁc
RNA interference at all, but rather was caused by
sequence-independent stimulation of Toll-like Receptor 3
and its downstream signaling pathway by dsRNA-like
molecules, leading to an interferon-g and IL-12 mediated
suppression of neovascularization (43). Thus, the possible
interplay of oligonucleotides with various members of the
Toll-like receptor family of cell surface proteins must be
considered in the design of experiments.
Mechanisms ofendocytosis and intracellular trafficking
In almost all instances, oligonucleotides (and their various
delivery agents) are taken up by some form of endocytosis.
Ultimately, the oligonucleotide must exit from the
endosome to reach its site of action in the cytosol or
nucleus. Thus, in order to understand key issues in the
intracellular delivery of oligonucleotides it is important to
consider the multiple routes of endocytosis and the
complex traﬃcking pathways that exist in cells.
Endocytosis is a blanket term that covers multiple
distinct uptake pathways including: (i) the ‘classic’
clathrin-coated pit pathway; (ii) the caveolar pathway;
(iii) one or more noncaveolar, clathrin-independent
pathways (CLIC pathways); (iv) macropinocytosis and
(v) phagocytosis (that mainly takes place in ‘professional
phagocytes’ such as macrophages and granulocytes)
(44,45). When the molecule being internalized is simply
dissolved in the ambient medium, the uptake process is
usually termed pinocytosis. When the molecule is bound
to a cell surface receptor the process is termed receptor-
mediated endocytosis. Each of the endocytotic pathways
is actin-dependent (with the possible exception of one
CLIC pathway), and the clathrin and cavelolar pathways
are dependent on the GTPase dynamin to pinch oﬀ
budding vesicles, while macropinocytosis is not dynamin
dependent. Caveosomes and CLIC vesicles are enriched in
‘lipid raft’ components including glycosphingolipids and
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followed by sequential intracellular traﬃcking into a
variety of low pH endomembrane compartments, includ-
ing early/sorting endosomes, late endosomes/multi-
vesicular bodies, and lysosomes; in some cases, recep-
tors/ligands can traﬃc to the Golgi complex. In many
instances, receptor and ligand are dissociated in the low
pH endosome environment, and in some cases the
receptor can recycle back to the cell surface via the
sorting endosomes (Figure 1).
The complex ﬂow of endomembrane traﬃc (48) is
regulated by the Rab family of small GTPases and by
tethering complexes, while vesicular fusion events are
controlled by SNARE proteins (49–51). The SNX (sorting
nexin) proteins also are important in sorting and cargo
retrieval from endosomes (52). The traﬃcking of inter-
nalized receptor and ligand can often be very complex and
dependent on the nature of the receptor, the physiological
status of the cell and the cell type. Some receptors can
enter cells via multiple pathways, for example, via both
clathrin-coated vesicles and caveolae (53). The route of
entry can aﬀect the ultimate fate and function of the
ligand–receptor complex. For example, at low ligand
levels the EGF-receptor is internalized via coated pits and
can continue to signal, while at high ligand concentrations
the receptor is ubiquitinated, internalized via a CLIC or
caveolar pathway, and degraded (54).
There are a number of tools commonly used to probe
pathways of internalization. For example, many studies of
oligonucleotide uptake have used pharmacological inhib-
itors that putatively block speciﬁc endocytotic pathways.
In reality, however, such inhibitors often aﬀect multiple
uptake pathways, as well as having many other eﬀects on
the cell. For example, although b-cyclodextrin is often
used to block uptake involving lipid rafts, it also aﬀects
clathrin-mediated endocytosis (55). Likewise, agents that
block macropinocytosis by aﬀecting actinomyosin func-
tion will also block other endocytotic pathways, as well as
having generalized eﬀects on the cytoskeleton (56,57).
Thus, results obtained with pharmacological inhibitors
need to be interpreted conservatively. Potentially, more
powerful approaches include using antibodies to key
marker proteins to co-visualize ﬂuorophore-tagged oligo-
nucleotides in speciﬁc endomembrane compartments (58),
and use of dominant-negative Rab proteins to interfere
selectively with traﬃcking patterns (59).
Although general aspects of the cellular uptake of oligo-
nucleotides have been studied for a long time and
extensively reviewed (7,60,61), it is only recently that
investigators have probed oligonucleotide internalization
in light of current understanding of endosomal traﬃcking
pathways. Whilenotenoughworkhasbeendonetoachieve
a broad consensus, some interesting examples of more
detailed traﬃcking studies have recently emerged (62–64).
Ligands for enhancingand targeting delivery
In this section, we will examine ligands that have been
used to attain cell-type selective targeting or to enhance
the uptake of oligonucleotides. For the sake of simplicity,
we have divided the discussion into agents that target
speciﬁc receptors (CTLs, cell targeting ligands) and agents
that enhance transmembrane permeation (primarily cell
penetrating peptides, CPPs).
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Figure 1. Endocytotic pathways. The ﬁgure depicts the multiple endocytotic pathways that may be involved in uptake of oligonucleotides. The black
arrows represent well-documented traﬃcking routes within the cell. The names in red indicate well-known protein markers for various
endomembrane compartments; in most cases, antibodies to these marker proteins are commercially available.
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extensively reviewed (65–69) and here we touch on only a
few key aspects. The prototypical CPPs derived from the
Tat and antennepedia transcriptional regulators have been
joined by a large number of new moieties. Most of these
are relatively short (9–30 amino acids) polycationic
peptides rich in argine and lysine, although some include
membrane-interactive hydrophobic sequences (Figure 2).
CPPs have been linked to proteins by recombinant DNA
techniques or chemically coupled to peptides, oligonucleo-
tides or nanocarriers, which then comprise the ‘cargo’ for
the CPP. Initially, CPPs were thought to convey their
cargo directly across the plasma membrane. However, it is
now clear that polycationic CPPs initially bind to cell
surface glycosaminoglycans; this is followed by endocyto-
tic uptake (possibly macropinocytosis) (70), and eventual
release of cargo from the endosome to the cytosol.
Although initial reports emphasized the great promise of
CPPs for delivery of macromolecules, recently there has
been some controversy as to just how eﬀective they
are (71). Certainly, the nature of the cargo (in terms of
size, charge and other molecular characteristics) has an
important impact on the eﬀectiveness and the toxicity of
CPP-mediated delivery (72–75). In a section below, we will
discuss how CPPs have been applied to oligonucleotide
delivery.
CTLs. A promising strategy is to deliver antisense and
siRNA oligonucleotides by use of a CTL that binds with
high aﬃnity to a cell surface receptor that is capable of
undergoing eﬃcient internalization. A wide variety of
potential ligands are available including antibodies (76),
polypeptides derived from phage display libraries (77) and
small organic molecules. Since various receptors are often
preferentially expressed on particular cell types, this
approach oﬀers the possibility of improved selectivity
for the oligonucleotide reagents. While a rich variety of
cell surface receptors are expressed in the human body,
work thus far involving delivery of oligonucleotides has
primarily focused on lipoprotein receptors (particularly
those in the liver) (78), integrins (79,80) and receptor
tyrosine kinases (81). Another potentially rich source of
targets is the G-protein coupled receptor (GPCR) super-
family, by far the largest family of receptors in the human
genome with approximately 850 members (82). GPCRs
have long been a major interest of the pharmaceutical
industry and thus a vast number of high aﬃnity small
organic molecule ligands for GPCRs are available or are
emerging via high-throughput screening procedures (83).
CELLULAR DELIVERY OF OLIGONUCLEOTIDE
CONJUGATES AND COMPLEXES
In this section, we discuss the use of CPPs and CTLs in the
delivery of antisense and siRNA oligonucleotides.
Emphasis here is on cellular studies, while in vivo work
is discussed in a following section. As a prelude, it is
important to recall that oligonucleotides do not permeate
intact cell membranes to any signiﬁcant degree via simple
diﬀusion, primarily because of the hydrophobic nature
of the membrane lipid bilayer. This is true for both
negatively charged siRNA or antisense moieties as well as
for molecules with uncharged backbones such as methyl-
phosphonates, PNAs and morpholinos (84,85).
CPP—oligonucleotide conjugates or complexes
A considerable eﬀort has gone into the preparation and
evaluation of conjugates of CPPs and oligonucleotides;
however, on the whole this has been only moderately
successful (86,87). Our laboratory has reported biological
eﬀects of conjugates of CPPs with anionic antisense
oligonucleotides (88,89), and others have reported on
CPP–siRNA conjugates (90,91). However, the bulk of
the literature suggests that CPPs are primarily able to
deliver oligonucleotides with uncharged backbones,
such as peptide nucleic acids and morpholino compounds
(92–96).
CPPs have been studied in connection with both
antisense and siRNA, and as chemical conjugates or
noncovalent complexes with the oligonucleotide. In
addition to the usual assays based on ‘knockdown’ of
mRNA by antisense or siRNA, another popular approach
has been the use of an assay based on the splice-correcting
properties of certain types of antisense oligonucleotides
(25). Brieﬂy, an aberrant intron is placed into a reporter
gene (luciferase, GFP) cassette and stably expressed in
cells. The aberrant intron results in incorrect splicing and
failure to produce functional mRNA and protein.
However, appropriate splice switching oligonucleotides
(SSOs) can correct splicing leading to expression of the
reporter gene. Since splicing only takes place in the
nucleus, this splice correction assay provides a convenient
positive read-out for delivery of the SSO to the nuclear
compartment.
Early work from our laboratory explored conjugates of
the CPPs Tat and Antennepedia (also know as penetratin)
with either standard phosphorothioate oligonucleotides
targeting the MDR1 drug resistance gene (89,97) or with
SSOs comprised of 20-O-Me phosphorothioates (88); in
both cases, the peptide and oligonucleotide were joined by
bio-reversible S–S bridges. In both types of assay, the
presence of the CPP enhanced biological eﬀects over those
Cell Penetrating Peptides (CPPs)
• Small peptides (usually less than 30 aa)
• Net positive charge (in most  cases)
• Translocate across plasma or endo-membranes
• Transport cargos into cytoplasm and nucleus
3132 7 (+) 30 WEAKLAKALAKALAKHLAKALAKALKACEA KALA peptide
2445 5 (+) 24 GALFLGWLGAAGSTMGAPKKKRKV MPG peptide
1428 9 (+) 9 RRRRRRRRR R9 peptide
2842 5 (+) 27 GWTLNSAGYLLGKINLKALAALAKKIL Transportan
1719 8 (+) 13 GRKKRRQRRRPPQ TAT
2247 7 (+) 16 RQIKIWFQNRRMKWKK Penetratin
MW Charge Length Sequence Name
Figure 2. Cell penetrating peptides. This describes some of the more
commonly used cell penetrating peptides in terms of molecular weight
and net charge.
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tide; additionally, a limited amount of microscopy was
done to evaluate intracellular distribution and evidence
was found for nuclear accumulation of the oligonucleo-
tide. In contrast, a later study from another group
examined a number of disulﬁde bridged conjugates
between various CPPs and 20-O-Me or LNA oligonucleo-
tides complementary to the HIV-1 TAR element (98). In
this case, there was little biological eﬀect unless endosome
disrupting agents were used; further, the oligonucleotides
were observed by ﬂuorescence microscopy to be restricted
to cytoplasmic vesicles, with no sign of nuclear localiza-
tion. The reason for the discrepancies between these two
sets of early studies is unclear. One possibility is that, in
our early studies, the peptide–oligonucleotide conjugates
became aggregated during use, and this actually enhanced
their eﬀectiveness. Interestingly, there have been several
reports of noncovalent complexes or aggregates between
anionic siRNA oligonucleotides and cationic CPPs that
seem to have provided moderately eﬀective delivery to
cells in culture. In one case, a modiﬁed version of the CPP
penetratin having endosomolytic properties was superior
to other CPPs that bound the siRNA equally well but
lacked endosome lytic ability (99). In another case, a
designed peptide comprised of both positively charged
residues and a fusion peptide sequence was found to
complex with siRNA and deliver it to the cytosol (100);
this approach has also been followed by other groups
(101). Whether conjugates or complexes are likely to
provide more eﬀective delivery of anionic oligonucleotides
in vivo is an important issue and will be further explored
below.
A number of investigators have evaluated conjugates of
CPP with oligonucleotides having uncharged backbones.
In one study, both stable and bioreversible disulﬁde
linkages were used to produce conjugates between various
CPPs and a PNA targeting the HIV-1 Tar motif (92).
Certain conjugates, particularly an R6–penetratin version,
demonstrated clear-cut biological eﬀects, although little
nuclear localization was seen by ﬂuorescence microscopy.
Several other CPP–oligonucleotide conjugates, with either
stable or disulﬁde linkages, were able to attain biological
eﬀects when chloroquine was used to enhance their release
from endosomes. An additional study used an R6–
penetratin conjugate of a PNA SSO to activate a luciferase
reporter gene; good eﬀects were attained at micromolar
concentrations (96). Another study also utilized PNA
SSOs coupled via disulﬁde bridges to various CPPs to
activate luciferase (93); here the transportan CPP was
found to be particularly eﬀective. Confocal microscopy
and use of endosomal markers indicated that the CPP–
PNA conjugates were most likely taken up by macro-
pinocytosis, but there was little evidence of nuclear
localization despite the observed eﬀects on splicing.
Studies from another group examined additional con-
jugates between PNA SSOs and various CPPs; they also
found that a transportan–PNA conjugate linked via a
bioreversible disulﬁde bridge was most eﬀective (94).
Recent studies have described a novel CPP termed ‘M918’
(63). When conjugated to PNA SSOs, M918 did not
require binding to cell surface glycosaminoglycans for
uptake (in contrast to Tat or penetratin). Nonetheless, it
entered cells by endocytosis and attained good biological
eﬀects. An interesting variation used CPP–PNA conju-
gates to target chromosomal DNA and cause eﬀects at the
transcriptional level (102).
Similar studies have also been done with CPP con-
jugates of morpholino oligonucleotides. In one very
comprehensive investigation, a variety of linkages were
formed between a morpholino SSO and several CPPs
(103). A peptide containing nine arginines was particularly
eﬀective and resulted in splice correction activity at
micromolar concentrations; ﬂuorescence microscopy indi-
cated some delivery of the oligonucleotide to the nucleus
as well as to intracellular vesicles. More recently, this
group has investigated the properties of conjugates
comprised of morpholino SSOs linked to CPPs containing
6-aminohexanoic acid residues (104,105), ﬁnding that
these have superior properties in terms of stability and
eﬀects on splicing.
The strategy of using CPP conjugates of SSOs having
uncharged backbones has recently been reviewed (106).
The overall picture seems to be that conjugates of various
CPPs with uncharged backbone oligonucleotides can enter
cells and eﬀectively alter RNA splicing processes. Various
CPPs diﬀer somewhat in their potency in this regard;
however, in most cases biological eﬀects are only attained
when the conjugates are used at micromolar concentra-
tions. This may indicate that most of the material taken up
by cells remains in endosomal compartments, with only a
tiny fraction reaching the nucleus where RNA splicing
occurs. One technical issue with many of these studies is
their reliance on a single model system involving correc-
tion of splicing in a modiﬁed HeLa cell line. As discussed
earlier, this system allows facile evaluation of whether a
splice switching oligonucleotide can reach the nucleus and
correct splicing of the aberrant reporter gene present
there. However, it seems unwise to rely so heavily on a
single cell type.
CTL–oligonucleotide conjugates orcomplexes
A number of studies have appeared recently using CTLs
for the delivery of antisense or siRNA. Some of these
studies had in vivo components that will be more fully
discussed in a section below. Here, we will focus on the cell
targeting and uptake aspects.
An aptamer-siRNA chimera targeting prostate-speciﬁc
membrane antigen (PSMA) was able to eﬀectively deliver
the associated siRNA to LNCaP prostate cancer cells; use
of plk-1 siRNA triggered apoptosis and resulted in cell
death both in culture and in a prostate tumor model (107).
In this case, concentrations in the 2–400 nM range were
eﬀective in attaining gene silencing in cultured LNCaP
cells, but not in PC-3 cells that lack PSMA. Other
interesting approaches to aptamer-mediated siRNA deliv-
ery have also been described (108). The conjunction of
nucleic acid aptamer technology and siRNA could
potentially be a very powerful avenue for developing
reagents for cell type selective regulation of gene
expression.
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ing the highly positive peptide protamine and an antibody
Fab fragment directed against the HIV-envelop glycopro-
tein; this proved to be an eﬀective carrier for siRNA
that is complexed noncovalently with the protamine
moiety. The chimeric protein was able to deliver an HIV
gag siRNA to HIV infected CD4+ T cells causing
inhbibition of HIV replication (109). A later version of
this approach used a conformation-sensitive single chain
antibody directed against the LFA-1 integrin to speciﬁ-
cally target siRNA to activated leukocytes (110); in this
case, the complexed siRNA was directed against the
CCR5 chemokine receptor. Eﬀective gene silencing was
obtained with amounts of siRNA in the sub-nanomol
range, although the exact concentrations used are unclear.
In another example, a small cyclic peptide that binds the
IGF1-receptor was able to deliver a PNA antisense moiety
to the cytoplasm of cells expressing this receptor (111).
A similar approach was also used for delivery of siRNA
directed to the signaling protein IRS1 (112). Here,
the peptide was conjugated via an NHS linker to a
50-aminolinked sense strand. Signiﬁcant silencing of the
target gene in MCF7 breast cancer cells was observed
using concentrations of the conjugate in the 100 nM
range.
In a similar vein, work from our laboratory has recently
shown that a bivalent RGD peptide having high aﬃnity
for the avb3 integrin can eﬀectively deliver conjugated
SSOs to melanoma cells that express this integrin (62).
Signiﬁcant eﬀects on splicing were attained with concen-
trations of conjugated SSO in the 10 nM range. The
uptake process of the conjugates was traced via confocal
ﬂuorescence microscopy; this indicated that the RGD-
conjugates entered via caveolae and other lipid raft-rich
structures and then eventually traﬃcked to the trans-golgi.
While substantial nuclear localization was not seen, the
biological eﬀects observed make it clear that some of the
SSO reached the nucleus. An important point is that
conjugates of this type display very little cytotoxicity, even
when used at concentrations far higher than those needed
to obtain a biological eﬀect.
Another study used a polymer as a carrier for both
siRNA and a targeting ligand. Thus, the polymer was
covalently ‘decorated’ with siRNA, polyethylene glycol
(PEG) and N-acetylgalactosamine as a ligand to target the
hepatic asialo-glycoprotein receptor (113). This approach
permitted eﬀective silencing of two endogenous genes in
cultured hepatocytes.
A particularly impressive study involved delivery of
siRNA to neurons in culture, and to the brain, by
complexation with a peptide that comprises a positively
charged (Arg9) sequence to bind the oligonucleotide and a
sequence that binds with high aﬃnity to the nicotinic
acetycholine receptor in neurons (114). The chimeric
peptide selectively delivered siRNA to neural cells expres-
sing the acetycholine receptor, but not to other cells, and
could silence a GFP reporter gene in the neuronal cells
when used at 10 pmol levels.
There is a striking functional contrast between the
studies utilizing CTLs for oligonucleotide delivery and
those using CPPs. In many cases, biological eﬀects were
attained using nanomolar concentrations of oligonucleo-
tides when delivery took place via receptor targeting,
whereas delivery using various CPPs attained strong
biological eﬀects only at micromolar concentrations. The
reason for this diﬀerential is unclear and may have little
to do with total uptake (although it is not possible to
reliably compare this parameter for the diﬀerent studies).
Possibly, a key issue is the intracellular traﬃcking
pathway(s) accompanying the various initial uptake
processes.
Nanocarriers foroligonucelotide delivery
A variety of supramolecular nanocarriers including
liposomes (115), cationic polymer complexes (116) and
various polymeric nanoparticles (117) have been used to
deliver antisense and siRNA oligonucleotides, as more
fully described in several recent reviews (3,9,38,118–122).
There is an enormous literature on use of various
nanocarriers to deliver nucleic acids; thus here we can
only touch on selected recent examples. Complexation of
oligonucleotides with various polycations is a popular
approach for intracellular delivery; this includes use of
PEGlyated polycations (123), polyethyleneamine (PEI)
complexes (124,125), cationic block co-polymers (126) and
dendrimers (127–130). Several cationic nanocarriers
including PEI and polyamidoamine dendrimers exert a
so called ‘proton sponge eﬀect’ that helps to release
contents from endosomes (131). Thus, as the nucleic acid–
polymer conjugate enters the low pH endosome compart-
ment, secondary amino groups in the polymer are titrated;
the necessary proton inﬂux also brings chloride and water
into the endosome, causing swelling and increased
leakiness. Other widespread approaches include use of
polymeric nanoparticles (132), polymer micelles (133),
quantum dots (134,135) and lipoplexes (136,137).
Lipoplexes comprised of cationic lipids also exert endo-
some destabilizing eﬀects (138); in this case, the cationic
lipids interact with anionic lipids of the endosome
membrane, leading to the formation of nonbilayer
structures and consequent endosome instability. In some
cases, nanoparticle approaches have been coupled with
targeting strategies. As one example, a lactosyl–PEG–
siRNA conjugate was complexed with polylysine to form
nanoparticles; these were eﬀectively delivered to liver
tumor cells via interaction with the asialo-glycoprotein
receptor (139). In considering the various types of
nanocarriers, it is important to keep in mind that the
carrier systems themselves can have signiﬁcant eﬀects on
gene expression, and may potentially cause toxicity. This
has been emphasized in two excellent recent reviews that
comprehensively describe eﬀects of polymers and nano-
carriers on gene expression (17,140).
IN VIVO DELIVERY OF OLIGONUCLEOTIDES
In this section, we will consider recent investigations
regarding the in vivo behavior of various oligonucleotide
conjugates and nanocarrier formulations. We will place
particular emphasis on several studies that have
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of systemically administered siRNA as a result of use of
delivery modalities. Some of these reports have been
discussed above in terms of results at the cell culture level.
Prior to initiating this discussion it is important to realize
that there is a dichotomy in the behavior of oligonucleo-
tides when comparing the in vivo situation to cell culture.
Thus, almost without exception, eﬀective use of antisense
or siRNA in cell culture requires a delivery agent such as a
cationic lipid; in contrast, many of the successful in vivo
studies with oligonucleotides have used ‘free’ compounds
(7,60). There seem to be two possible interpretations of
this dichotomy. One version suggests that cells undergo
radical changes in organization and gene expression as
they go from a 3D tissue environment to a 2D culture
environment and that in this process key oligonucleotide
transporters are lost. While it is clear that cells do undergo
dramatic changes in the transition from 3D to 2D (141), it
seems unlikely to us that the same oligonucleotide
transport systems would be lost in every single type of
cell. Another interpretation is a pharmacodynamic one.
Because of experimental constraints, in culture cells are
only brieﬂy exposed to the oligonucleotides; in contrast,
most in vivo therapeutic experiments involve multiple
doses and protracted exposures, thus perhaps allowing
gradual intercellular accumulation of oligonucleotides.
Surprisingly, this important dichotomy has not been
carefully addressed via experimentation.
Biological barriers toin vivodelivery ofoligonucleotides
In planning for the eﬀective delivery of oligonucleotides, it
is essential to understand key aspects of endocytosis and
intracellular traﬃcking at the cellular level. However,
in vivo there are a number of other important parameters
to consider as well (Figure 3). Essentially, a series of
biological barriers stand between the newly administered
oligonucleotide and its ultimate site of action in the
cytosol or nucleus of tissue cells (142). For ‘free’
oligonucleotides or small conjugates, an important limita-
tion is rapid excretion via the kidney. Molecules less than
5000 molecular weight are rapidly ultraﬁltered in the
glomerulus and, in the absence of re-uptake, are accumu-
lated in the urine (143). This picture is somewhat altered
with oligonucleotides that bind strongly to plasma
proteins thus retarding ultraﬁltration (144). The vascular
endothelial wall comprises another major barrier, espe-
cially for larger carriers. In general, molecules with a
diameter of >45A ˚ (equivalent to about the size of an
immunoglobulin) do not readily pass across the capillary
endothelium and thus cannot eﬃciently enter the extra-
cellular ﬂuid that bathes tissue cells (145). In addition, it is
not only the size but also the shape of the macromolecule
or nanocarrier that aﬀects its ability to traverse the
endothelium (146,147). In a few tissues, including liver and
spleen, the vascular endothelium is ‘fenestrated’ with gaps
that allow the egress of macromolecules and nanoparticles
up to about 200nm diameter (148). In addition, work in
xenograft tumors has given rise to the concept that the
tumor vasculature is far ‘leakier’ than normal vasculature,
thus also allowing egress of relatively large macromole-
cules and nanoparticles, the so-called ‘EPR eﬀect’
(enhanced permeation and retention) (149). However, it
is not clear that spontaneously occurring tumors in
animals or humans uniformly display such increased
leakiness. Further, tumors often exhibit other properties,
such and increased interstitial pressure, that would tend to
oppose delivery of nanocarriers to the tumor (150).
Although one must be concerned about the issue of
vascular permeability, it is also important to realize that
the vascular endothelial cells themselves can be portals for
therapy. This is especially true in sites of inﬂammation,
where the endothelium upregulates key cell surface
proteins including VCAM, ICAM and P-Selectin (151)
or in angiogenic endothelium where the avb3 integrin is
upregulated (152); thus, in both situations there is
enhanced expression of receptors that can be addressed
via CTLs linked directly to oligonucleotides or to
nanocarriers. There are already many examples in the
literature where endothelial receptors, especially avb3,
have been targeted by various macromolecular or
nanoparticle carriers bearing drugs or imaging agents
(153–155).
Even if a nanocarrier exits the vasculature, it still needs
to diﬀuse through the extracellular matrix to reach tissue
cells; the ECM is comprised of a dense meshwork of
proteins and proteoglycans that can hinder nanocarrier
diﬀusion and in some cases may even tightly bind the
carrier (142). Another key barrier is presented by the
phagocytes of the reticuloendothelial system (RES). These
cells monitor the blood and remove foreign materials such
bacteria and viruses; unfortunately, they also tend to treat
administered macromolecules and nanoparticles as for-
eign, thus accumulating these materials in hepatic Kupﬀer
cells, splenic macrophages and other sites rich in
phagocytes (156,157). This process can be attenuated to
some degree by ‘passivating’ or ‘stabilizing’ the surfaces
In Vivo Barriers to the Effective Delivery of Antisense
and siRNA Oligonucleotides
1.  Rapid excretion via the kidney
2.  Degradation by serum and tissue nucleases
3. Uptake by the phagocytes of the reticuloendothelial system
leading to sequestration in liver and spleen
4. Failure to cross the capillary endothelium
5. Slow diffusion/binding in extracellular matrix
6. Inefficient endocytosis by tissue cells
7. Inefficient release from endosomes
Figure 3. In vivo barriers. The ﬁgure lists key barriers to eﬀective in vivo
delivery of oligonucleotides. Rapid excretion is an issue for low
molecular weight compounds. Clearance by phagocytes, capillary
permeability and slow diﬀusion in the extracellular matrix apply to
larger molecules and nanoparticles. Both small and large delivery
agents can be aﬀected by poor cellular uptake and ineﬃcient release
from endosomes.
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(158); PEGlyation serves to reduce the adsorbtion of
‘opsonins’, plasma proteins that enhance phagocytosis,
but this tactic is never completely eﬀective. PEG-
conjugated nanocarriers can remain in the circulation
much longer than unmodiﬁed versions, but ultimately
signiﬁcant clearance by the RES takes place. In summary,
a variety of considerations at the both cellular and
whole organism levels are involved in the design of
eﬀective in vivo delivery strategies for therapeutic
oligonucleotides.
In vivodelivery ofoligonucleotide conjugates
At this point, relatively little is known about the in vivo
behavior of ligand–oligonucleotide conjugates. A recent
study examined the biodistribution of a conjugate between
an arginine-rich CPP and a morpholino oligonucleotide
and suggested increased uptake in many tissues as
compared to free oligonucleotide (159). Studies of
cholesterol-linked siRNAs indicated that their association
with serum proteins plays an important part in their
pharmacokinetics, biodistribution and ultimate eﬀects on
gene expression in liver cells (14). Thus, the elimination
half-life and tissue accumulation of an apolipoprotein
B-targeted siRNA was substantially increased via choles-
terol conjugation, leading to enhanced reduction of target
mRNA and protein and consequent eﬀects on blood
cholesterol levels. A more detailed analysis of the behavior
of lipidic conjugates of siRNA indicated that HDL and
LDL were the primary carriers for cholesterol-linked
siRNA, while conjugates of medium chain fatty acids
primarily bound albumin (160). This report further
demonstrated the key role of the LDL-and HDL-receptors
in tissue uptake of cholesterol siRNA, with uptake via the
LDL-receptor predominating in liver. Interestingly, this
report also suggests a very novel mechanism for cell entry
of siRNA via lipoprotein receptors. Thus, instead of
simple receptor-mediated endocytosis of the siRNA-
loaded lipoprotein, the authors suggest that the siRNA
is passed from the lipoprotein receptor to Sid 1, a
multispanning plasma membrane protein whose homolog
in C. elegans can potentiate RNAi uptake and eﬀects.
Interestingly, other groups, working with mammalian cell
cultures, have also linked Sid1 to intracellular uptake of
siRNA (161,162). If these observations are generalizable,
it would have a profound eﬀect on our understanding of
the transport of siRNA and on approaches to delivery and
therapeutics.
Cholesterol-conjugated siRNA has also been adminis-
tered directly into the lung via intratracheal instillation.
In this case, the target was p38 MAP kinase mRNA.
Signiﬁcant target reduction was attained with the choles-
terol siRNA but not with CPP-conjugated siRNA; indeed,
in this case, potentially toxic results were observed (163).
An interesting variation on delivery via lipid conjugation
is embodied in a recent report on a-tocopherol modiﬁed
siRNA; this lipidic material also promotes siRNA delivery
via binding to serum proteins and lipoproteins, but may
involve a diﬀerent set of binding partners (164).
Invivo delivery of oligonucleotides using nanocarriers
A variety of nanocarriers have been developed to promote
the eﬀective in vivo delivery of oligonucleotides, with the
emphasis on siRNA. An impressive early study involved
complexation of siRNA with cationic cyclodextrin poly-
mers to form nanoparticles, and used transferrin to target
the nanocomplex to Ewing’s sarcoma tumor cells that
express high levels of the transferrin receptor (165).
Delivery of siRNA targeting the EWS-FLI1 oncogene
product resulted in reduced tumor growth. This same
technology has more recently been tested for safety in
primates, but with the active material being siRNA tar-
geting the M2 subunit of ribonucleotide reductase (166).
In another study involving in vivo targeted delivery, ‘self
assembled nanoparticles’ (a form of lipoplex) were used to
deliver siRNA to tumors (167). Anti-EGF-receptor
siRNA (as well as carrier DNA) was complexed with
protamine and then with lipid. The particles were
passivated with PEG and targeted using anisamide as a
ligand. The nanoparticles were used to treat mice bearing
xenografts of the NCI-H460 tumor, which expresses high
levels of a cell surface receptor that binds anisamide; this
treatment resulted in partial reduction of tumor growth.
In addition, this study examined the pharmacokinetics
and biodistribution of the administered siRNA, observing
extensive tumor uptake for the targeted nanoparticles but
not untargeted controls.
A very recent study also used a liposome-type carrier
for targeted in vivo delivery of siRNA (168). Here,
uncharged lipids were used to form small unilamellar
liposomes. These were covalently linked to hyaluronan to
stabilize and passivate the liposomes, which were then
further conjugated to an antibody that binds the beta7
integrin subunit. The antibody-targeted liposomes were
then ‘loaded’ with a protamine–siRNA complex. This
technology was used to selectively deliver cyclin D1
siRNA to beta7-positive leukocyte subsets involved in
intestinal inﬂammation, resulting in amelioration of an
experimentally induced colitis.
Stable nucleic acid lipid particles (SNALPs), a type of
liposome, have proven very eﬀective for delivery of siRNA
to the liver (169). In this case, apoB siRNA was used to
treat cynomolgus monkeys resulting in substantial silenc-
ing of apoB mRNA expression followed by reduced
protein levels and reductions in blood cholesterol.
Extensive pharmacokinetic studies were also performed.
The SNALPs are not a targeted nanocarrier, but rather
rely on stability and long circulation time to attain
eﬀective delivery. Another promising approach using
liposomes involved the suppression of liver ﬁbrosis via
delivery of siRNA targeting a heat-shock protein (HSP47)
in hepatic stellate cells. These cells express a receptor for
vitamin A and the liposomes were thus complexed with
this substance in order to attain targeting both in hepatic
cell cultures and in vivo (170). This study was notable for
the very extensive validation of the in vivo therapeutic
response.
Another interesting approach, discussed previously,
involves creating protein chimeras of Fab or scFv
antibody components with protamine, followed by
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approach was used to deliver growth inhibitory siRNAs
in vivo to B16 melanoma cells engineered to express the
HIV envelop glycoprotein, or to breast tumor cells over-
expressing ErbB2, using the appropriate antibody com-
ponent in each case. A modiﬁcation of this approach (110)
used a protamine chimera with a conformation-sensitive
single chain antibody directed against the LFA-1 integrin
to speciﬁcally target siRNA in vivo to lymphoid tumor
cells that express the activated form of LFA-1 (110).
Polymer systems have also been used for targeted in vivo
delivery. Thus, as mentioned earlier, a polymer nanocar-
rier linked to N-acetylgalactosamine was used to promote
selective uptake by hepatocytes (113). In vivo, this system
was able to eﬀectively deliver apoB siRNA to mouse liver,
resulting in gene silencing and reduced systemic choles-
terol levels. Somewhat similarly, a system involving an
RGD-conjugate of PEI was used to deliver siRNA
targeting VEGF-receptor to tumor vasculature (125).
Finally, as mentioned earlier, delivery of siRNA to the
brain was attained by formation of a nanocomplex with a
peptide comprising positively charged sequence to bind
the oligonucleotide and a sequence that binds with high
aﬃnity to the nicotinic acetycholine receptor in neurons
(114). Use of an antiviral siRNA provided protection
against a potentially fatal viral encephalitis in mice. It is
very surprising that the siRNA nanocomplex was able to
cross the blood–brain barrier since even most small
molecule drugs fail to do so. However, in this case it is
possible that the presence of an active viral infection
altered the permeability of the barrier.
In summary, several types of nanoparticle technologies
have eﬀectively delivered siRNAs to the liver, to tumors,
or to inﬂammed tissues. It should be noted, however, that
the vasculature in these tissues diﬀers substantially from
that more generally present in the body, as has been
discussed earlier. Thus, it is unclear whether these
approaches can be generalized to other tissues. Several
of the studies mentioned above have also been reviewed
recently in another venue (171).
CONCLUSIONS
As reﬂected in this article, a great deal of eﬀort is currently
focused on the delivery of therapeutic oligonucleotides.
Signiﬁcant strides have been made, but the issue has not
been fully resolved. Thus, it seems valuable to compare
and contrast in broad terms the various strategies that are
being pursued. Perhaps the most signiﬁcant parameter to
consider is the size of the moiety being delivered,
contrasting nanoparticles that have diameters in the
50–200nm range and molecular weights in the millions
to monomolecular oligonucleotide conjugates with mole-
cular weights in the thousands. Another key issue is charge
since both polyanionic and polycationic molecules or
nanocarriers can interact with blood proteins to incite
toxicity or aﬀect biodistribution (172,173).
Nanoparticles of various types oﬀer many advantages
as delivery agents. They can carry a large ‘payload’
comprising hundred or thousands of copies of the siRNA
or antisense oligonucleotide. They can be decorated with
multiple copies of targeting ligands, thus providing high-
avidity interaction with the target cells. Nanoparticles can
be designed to release their contents at prescribed rates
and can also be engineered to assist in the release of their
contents from endosomes. Novel approaches for produ-
cing extremely uniform nanoparticles with controllable
drug release characteristics are becoming available (174).
Technologies for producing nanoparticles are reasonably
mature thus permitting relatively facile scale-up for
clinical studies (although reliable large-scale formulation
of nanoparticles under GMP conditions is not without
problems). Additionally, regulatory agencies are familiar
with nanoparticles as delivery agents, based in part on the
several liposomal drugs now on the market (175). Many of
these useful aspects of nanoparticle-mediated oligonucleo-
tide delivery are implicit in the studies reviewed earlier.
However, the many positive features of nanoparticles are
counterbalanced by some important negative ones. First,
despite advances in using PEG or other hydrophilic
polymers for stabilization, a large fraction of the injected
dose of nanoparticles will accumulate in the liver, and
much of that will be taken up by hepatic phagocytes.
Thus, a signiﬁcant portion of the dose of oligonucleotide
will wind up at the wrong site, where toxic eﬀects could
potentially occur. Second, because of the vascular
endothelial barrier, nanoparticles can only reach certain
tissues, such as liver and spleen, where gaps in endothe-
lium occur. This is one of the reasons that the various
siRNA and antisense companies have focused so strongly
on diseases that involve the liver. Nanoparticles that have
long circulation times can also accumulate in some types
of tumors due to the EPR eﬀect; inclusion of a ligand that
binds a receptor on the tumor cells can then promote
uptake and intracellular delivery (176). However, what
nanoparticles cannot do is to access parenchymal cells in
most normal tissues; they are simply excluded by the
endothelial barrier. Thus, many potential disease targets
will not be addressable by oligonucleotide-based thera-
peutic platforms that involve nanoparticles.
In contrast, oligonucleotide conjugates are usually far
smaller than the pores in normal vascular endothelium;
thus, in principle, they should be able to access virtually all
tissues, just as conventional drugs do (with the exception
of the central nervous system). It should be noted that
in some cases the oligonucleotide conjugate may be rapidly
excreted via the kidney. Clearly, the detailed physical and
chemical properties of individual oligonucleotide conju-
gates will inﬂuence their interactions with plasma proteins
and their overall biodistribution; however, to a ﬁrst
approximation, the relatively small size of oligonucleotide
conjugates implies a fundamental diﬀerence in their in vivo
behavior as compared to nanoparticles. Nonetheless, there
are some liabilities associated with this approach. First,
each conjugate requires a separate synthesis, whereas a
particular type of nanoparticle can potentially accomodate
a variety of diﬀerent oligonucleotides. Second, since only a
single ligand is conjugated to the oligonucleotide this
implies a lower-aﬃnity interaction with target receptors
than is the case for multivalent nanoparticles. Another
issue concerns release from endosomes subsequent to
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moiety and an endosome escape moiety into a mono-
molecular oligonucleotide conjugate; at minimum, the
chemistry will be quite diﬃcult.
Thus, both nanocarriers and molecular conjugates
exhibit pluses and minuses as delivery agents.
Ultimately, the most attractive delivery system may turn
out to be neither a relatively small monomolecular
oligonucleotide conjugate nor a very large nanoparticle
or nanocomplex. Rather it may be an intermediate-sized
moiety, perhaps comprised of oligonucleotides and
targeting agents covalently linked to a small polymer
(113) or protein that is large enough to avoid rapid
excretion but yet small enough to be able to pass the
vascular endothelial barrier. This approach may oﬀer
some of the high payload and high-aﬃnity targeting
aspects of nanoparticles without the constraints due to
relatively large particle size. This is certainly an appealing
approach and one that our group is actively pursuing.
An issue that applies to both conjugates and nanocar-
riers is the choice of accessory ligands. As mentioned
earlier, there have been a number of attempts to improve
both cellular uptake and endosomal release of oligonu-
cleotides using CPPs. Surprisingly, however, this has not
proven very eﬀective, at least for monomolecular oligo-
nucleotide conjugates. On the other hand, studies of
polymolecular complexes of CPPs with oligonucleotides
have seemed more promising; perhaps it requires multiple
copies of CPPs to attain strong endosome destabilizing
eﬀects. As discussed earlier, use of cell targeting ligands
that bind to speciﬁc receptors seems a more productive
strategy. However, in most of the examples cited, while the
targeting ligand can certainly enhance uptake, it is not
clear that endosomal release is also enhanced. Perhaps one
aspect of the receptor targeting strategy may entail
diﬀerential opportunities for release from endosomes as
the internalized oligonucleotide traﬃcks through diﬀerent
endomembrane compartments. Thus, it would be inter-
esting to see if the same oligonucleotide, taken up via two
diﬀerent receptors, had the same or diﬀerent ultimate
biological eﬀect. Certainly, it will be important to use
current cell and molecular biological approaches to learn
more about the details of intracellular traﬃcking of
oligonucleotides and conjugates.
Another issue concerns the use of conjugates versus
complexes. Some of the most exciting in vivo observations
to date have involved noncovalent complexes between an
oligonucleotide and a delivery agent (109,114). In most
cases, however, the stoichiometry and physical character-
istics of these complexes are essentially unknown. This
raises issues concerning scale-up, reproducibility and the
pharmaceutical acceptability of these approaches.
Conjugates have the advantage of being well-deﬁned
molecular entities that may be easier to move along the
path toward large-scale production, commercialization
and clinical utilization.
In summary, while much progress has been made in the
area of delivery of antisense and siRNA, much remains to
be done. It will be important to pursue basic studies
concerning both subcellular traﬃcking of olignucleotides
and their detailed biodistribution in animals. A measured
approach may, in the long run, serve the ﬁeld better than
hasty attempts to ‘hit a home run’ by bringing poorly
characterized delivery strategies prematurely into the
clinic.
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